What Is BPC-157? The Healing Peptide Endorsed by Joe Rogan and Andrew Huberman
What Is BPC‑157? Benefits, Safety, and What Human Studies Actually Show
The Evidence, Honestly Graded.
BPC-157 gets discussed online with a lot more certainty than the human evidence currently supports. That doesn't mean it doesn't work. It means the evidence needs to be graded honestly, by type, before you decide what to believe.
Decades of animal data.
One graded conclusion.
How we researched this
Vendor, clinic, forum and social content informed which consumer questions we address. They are never used as scientific evidence. Where a number couldn't be traced to a real source, we say so instead of repeating it.
The BPC-157 TL;DR
If you only read one section, start here. This compares the most common BPC-157 claims with what the evidence actually shows.
What we know
Real, direct mechanistic and animal evidence tied to tissue repair, studied since 1993.1
What we don't know
Whether any of it translates to a human benefit. The one controlled human GI trial is an unpublished abstract.13
What that means for you
Treat claims as animal-borrowed hypotheses. Not approved, not legal to compound, prohibited for tested athletes.
The human evidence isn't "limited." It's tiny.
What BPC-157 actually is
NOT A VERIFIED SEQUENCE MAP
BPC-157 stands for Body Protection Compound 157, a synthetic, 15-amino-acid peptide fragment modeled on a protective protein researchers identified in human gastric juice. It's built to be stable enough to survive conditions that would normally break a peptide down quickly, which is part of why it's marketed in oral capsules at all.16
It's investigational: still a subject of research, not an approved treatment for anything, anywhere.
Research accelerates
Human trial abandoned
Regulatory tug-of-war
Why Joe Rogan and Andrew Huberman come up
A personal account of use is not clinical evidence. Here's the distinction, kept explicit.
What was said
What that actually establishes
A personal account of one person's experience, self-reported, with no control group and no measured outcome.
Neither claimed BPC-157 is proven to work, and neither is a substitute for the evidence graded throughout this page.
An evidence ladder nothing has climbed to the top of
Five rungs, from a cellular clue to replicated clinical proof. Every study we could find sits somewhere on this ladder, and the top rung stays empty.
clinical evidencethe proof threshold
Explore every study
The same eight studies from the ladder above, filterable, with the primary source one click away.
Lee & Burgess: IV safety pilot
No adverse effects, no meaningful biomarker change.
Not a pharmacokinetic study, tolerability only.
Ruenzi et al.: PL 14736 enema, ulcerative colitis
The only controlled human trial identified for any BPC-157 indication.
Unpublished conference abstract, never a full peer-reviewed manuscript.
Lee & Padgett: intra-articular knee injection
Reported symptom improvement across several knee-pain diagnoses.
No control group, no blinding.
Lee, Walker & Ayadi: interstitial cystitis
Reported symptom improvement, again uncontrolled and from the same small author network.
Uncontrolled, same small research network.
Hsieh et al.: VEGFR2-Akt-eNOS activation
The strongest, most direct mechanistic finding available.
Real and direct, but from one paper, one lab, one model.
Chang et al.: tendon fibroblast healing
Direct evidence of fibroblast migration.
Measures cell movement, not collagen production directly.
Xu et al.: preclinical safety/toxicology
No lethal or minimum-toxic dose was identified across mice, rats, rabbits and dogs.
The closest thing to a formal safety dataset that exists, and it's all animal.
WO2014142764A1: stable salt formulation
The source of the "90% oral bioavailability" number circulating online. Full breakdown in Section 07.
The patent never measured bioavailability at all.
How it's hypothesized to work
This is the strongest, most directly-supported part of the BPC-157 story: a real signaling cascade, observed directly in cells and animals. It's also the part most likely to get overstated into a human outcome. Select a stage.
VEGFR2 activation
VEGFR2 is a receptor on the surface of cells lining blood vessels. In a 2017 study, BPC-157 caused human vessel-lining cells to take this receptor inside the cell and switch on its signaling: the first domino in a chain researchers believe leads toward new blood-vessel growth.1
A 2004 study inferred possible central effects from rat brain serotonin/dopamine changes after peripheral dosing: real, but indirect.18 A more rigorous 2022 study directly tracked radiolabeled BPC-157 in the body, and found brain tissue had the lowest concentration of any tissue sampled.8 The best direct-measurement evidence argues against it crossing the barrier in meaningful amounts.
BPC-157 and gut research
This is the single most active area of both research and regulatory attention right now, and where the gap between animal data and human evidence is widest.
Decades of animal data, one thin human trial
BPC-157 was originally isolated from gastric juice, so gut protection is its oldest research thread. Decades of animal studies, mostly from one concentrated research network, report protection against stomach ulcers, faster healing of surgical bowel injuries, and improved markers of intestinal-barrier integrity.19
Consumer shorthand, not literature terminology. The research measures "intestinal permeability" or specific tight-junction markers in defined animal injury models.
Tracing the one gut claim that has any human evidence
Animal models
Decades deep: ulcer protection, fistula healing, colitis models. One research network.
Human UC evidence
One trial, ~46 patients, positive, but never published beyond an abstract.
Human Crohn's evidence
None. No published human evidence exists for Crohn's disease at all.
FDA's Pharmacy Compounding Advisory Committee discussed BPC-157 specifically for ulcerative colitis in July 2026. That is a regulatory-access discussion, not a scientific finding. See Section 09 for the full sequence.
Beyond the gut: tendon, muscle, nerve
Real fibroblast activity, zero human trials
BPC-157's other major research thread is musculoskeletal: tendon, ligament and muscle injury in animal models, where it's reported to promote fibroblast migration and functional recovery.2
Direct fibroblast migration data, rat Achilles model
Reported functional recovery in injury models
Rests on the same biodistribution evidence discussed in Section 04
No dedicated primary research identified in this review
As with the gut research, all of it is preclinical: no human tendon, muscle or nerve-repair trial has been published.
Oral vs injectable, and what "90% bioavailability" actually means
This is the article's most original section: a number repeated across nearly every oral BPC-157 product page, traced back to what it actually measured.
bioavailable”
Where the number appears
Used to justify delayed-release capsules across the market, repeated so often it reads as an established fact.
Patent source
Filed 2013 by Diagen d.o.o., BPC-157's own patent holder.
What the patent actually measured
~90% of the arginine-salt form stayed intact after exposure to simulated stomach acid, in a test tube, not a body.
Acid stability vs. bioavailability
The patent contains no bioavailability figure at all. No peer-reviewed study has ever measured plasma BPC-157 in a human after an oral dose, for any formulation.
Current answer, human oral bioavailability
A companion "~3% bioavailability" figure, usually attached to the acetate salt, couldn't be traced to any peer-reviewed study, patent, or manufacturer document at all.
Which routes has research actually used?
What research has actually studied
- SpeciesRats, dogs, mice, rabbits; fewer than 20 total human subjects, safety-only
- RouteInjectable, intra-articular, intravesical, rectal
- Oral human PKNever measured, in any study, ever
What a consumer actually buys
- FormatOral capsule, gummy, or sublingual; zero human PK data
- DoseA fixed label amount (commonly 250-500mcg) with no pharmacokinetic basis
- Basis for useMarketing built on a stability figure re-labeled as bioavailability
Safety, side effects & what's unknown
No study has found clear evidence of harm. That is not the same statement as "BPC-157 is safe." With fewer than 20 total human subjects studied, for days to weeks, absence of evidence and evidence of absence are two different things.
Current regulatory status: FDA & WADA
Three separate things get blurred together in most coverage of this topic. Here they are, kept apart.
Recommended against
FDA's own briefing document proposed BPC-157 not be added to the approved compounding list, citing insufficient evidence.22
Recommended inclusion anyway
July 23 to 24, 2026: an 8-6 vote (per independent outlets) recommended adding it anyway, against staff's own recommendation.
Not authorized
Confirmed against 21 CFR 216.23: not on the compounding list, not FDA-approved for anything.23
A recommendation is not the same thing as an approval. Staff and committee disagreed, and neither one changes what's authorized today.
Flagged as a safety risk
FDA places BPC-157 on its Category 2 compounding list.
Flag removed
Current FDA pages no longer list it under Category 2.
Reviewed for colitis
Staff recommend against; the committee votes to recommend it anyway.
Still not authorized
No rulemaking has occurred. Compounding remains unauthorized.
WADA / athlete status
Confirmed against USADA's current page: BPC-157 is prohibited under the S0 Non-Approved Substances category, for all athletes, at all times. Enforcement doesn't require a positive test; possession or admission can be sufficient.
(Some sources also claim a second "S2" classification; USADA's own text does not confirm this, so this page reports the verified S0 status only.)
What BPC-157 has not been shown to do
Check a BPC-157 claim
Real claims that circulate online, graded against the evidence above. Filter by topic, then open one to see the full reasoning.
That BPC-157 helps repair injured tissue.
Direct, well-sourced mechanistic and animal evidence for tissue-repair pathways (Section 04).
The mechanism is directly observed, not extrapolated, but only in cells and animals.
A published human tissue-repair trial with a measured clinical endpoint.
That BPC-157 repairs the gut lining or reverses leaky gut.
The only human GI trial is an unpublished abstract. Everything else is animal (Section 05).
Encouraging animal data, but the human evidence never cleared peer review.
Ruenzi et al., cited in FDA briefing 193343
Publication of a peer-reviewed human GI efficacy trial.
That BPC-157 speeds tendon healing.
Real animal and in-vitro fibroblast evidence. Zero human tendon-repair data exists.
Direct cell-migration evidence, but no human trial to confirm it generalizes.
A human tendon-injury trial with imaging or functional outcomes.
That oral BPC-157 capsules produce a systemic effect.
No human oral pharmacokinetic data exists at all (Section 07): unstudied, not proven.
"Unknown" because it's genuinely untested, not because it's disproven.
He et al. 2022 (IV/IM only), ClinicalTrials.gov
A human oral PK study measuring plasma concentration.
That BPC-157 has direct central nervous system access.
The best direct-measurement study found the lowest concentration in brain tissue of anywhere sampled (Section 04).
An early indirect study suggested it; the more rigorous direct study contradicts it.
2022 radiolabeled biodistribution study, PMC9794587
A direct human or animal brain-concentration study finding otherwise.
That BPC-157 raises or lowers testosterone.
No study in any species was found measuring this at all (Section 08).
There is nothing to grade. No research exists either direction.
None identified
Any study, animal or human, measuring hormone levels.
That BPC-157 carries no meaningful risk.
No long-term data exists in humans or animals; short-term signal rests on fewer than 20 people (Section 08).
Absence of evidence of harm is not the same as evidence of safety.
Lee & Burgess 2025, Xu et al. 2020
A long-term human safety study with a meaningful sample size.
That BPC-157 is or soon will be FDA-approved.
Not approved for anything; not currently authorized for compounding either (Section 09).
A committee recommendation is not a rulemaking or an approval.
21 CFR 216.23, FDA briefing 193342
Completed FDA/HHS rulemaking.
What we know
- Originates from a gastric-juice protein, first described in 1993
- Directly activates VEGFR2-Akt-eNOS in cell and animal studies
- Not FDA-approved; compounding not currently authorized
- Prohibited for tested athletes under WADA's S0 category
What we still don't know
- Whether it works in humans, for any condition; zero peer-reviewed human efficacy data exists
- How much of an oral dose reaches the bloodstream; never measured, for any formulation
- Long-term safety, at any dose, in humans or animals
- Whether the theoretical cancer/angiogenesis concern is real or negligible in practice
- Any effect on testosterone or other hormones; no research exists either way
- Whether or when the FDA's regulatory door will actually open
- Whether the strong version of the "crosses the blood-brain barrier" claim is true
Frequently asked questions
Worth asking a healthcare professional directly, not just a search engine.
In cell and animal studies, it activates signaling pathways tied to new blood-vessel formation and tissue repair (Section 04). Whether that translates to a measurable effect in a person hasn't been established.
It's one of the most studied peptides for gut protection in animals. In humans, the only controlled trial is an unpublished abstract in ulcerative colitis (Section 05): encouraging, but far short of proof.
It's sold that way, but no study has ever measured how much of an oral dose reaches the bloodstream in a human (Section 07). "Sold as oral" and "studied as oral" are not the same thing.
No. It's not approved for any indication, and as of today it isn't authorized for pharmacy compounding either (Section 09).
No signal of harm in the very limited data available (Section 08), but that data covers fewer than 20 people for days to weeks, so this is a thin reassurance, not a clean bill of health.
No research in any species was found addressing this at all. It's a claim with no evidence base either way.
It's prohibited at all times under WADA's S0 category (Section 09), and a positive test isn't required for a violation.
Same molecule, entirely different evidence base: every human study used injectable, intra-articular, intravesical or rectal routes. Oral use has no human data behind it at all (Section 07).
References
Primary sources, prioritized. Vendor and forum sources are never cited as evidence.